Precipio's $7M Breakout: The Flywheel Finally Spins
Record product revenue, positive EBITDA, and a second consecutive quarter of organic cash generation mark a turning point for the diagnostics underdog.
PRPO · Earnings Call · 2026-08-17
A Quarter That Changes the Narrative
For a company that spent years in the red, the second quarter of 2026 was a watershed. “For the first time in Precipio's history, quarterly revenue surpassed $7 million.” — Ilan Danieli, Executive · 2026-08-17 More importantly, the mix shifted decisively toward the higher-margin product revenues line, which hit $900,000 — a 35% sequential jump and 21% above the prior record. The numbers are not just a blip: adjusted EBITDA turned positive at ~$400,000, and the company generated ~$700,000 in operating cash flow, ending the quarter with over $3 million in cash after increasing it by $500,000 organically. “We achieved that cash position organically without raising capital.” — Ilan Danieli, Executive · 2026-08-17
This is a decisive turn from the story told just three months prior, when Q1 revenue was flat and cash burn dominated the discussion. The fundamentals axis confirms the trajectory: total revenue has more than doubled over five years, and as of the latest filing, revenue sits at $15M (TTM), up ~43% year-over-year. The effective net cash position, while still modest, has swung from deep negative to positive over the past year, reinforcing the CEO's claim that the operational model is finally self-funding.
The Flywheel in Action
The strategic heart of the quarter is the validation of the "flywheel" model — using the in-house pathology lab to identify diagnostic pain points, develop solutions, validate them in a real-world clinical setting, and then commercialize them to other labs. “Our model is different. Our clinical experience drives product development because we already have the clinical laboratory.” — Ilan Danieli, Executive · 2026-08-17 The commercial pipeline is the tangible evidence: the team added ~10 new distributor reps (now covering Thermo Fisher, McKesson, Medline, and Cardinal), identified 25+ new qualified customers, and held 30+ meetings with them during the quarter. This is exactly the "recipe" the CEO has been experimenting with for years — each distributor has a different structure and incentive, and the company is finally figuring out how to work with each.
The Pathology division remains the stable foundation, growing modestly to $6.1M, but the real upside is in the product business. The flagship is the rapid AML assay, which delivers time-critical molecular results in one day vs. the typical 10–14 days. The CEO emphasized that this is not theoretical: every week, several AML samples come through their lab, and same-day results are already impacting patient care. This is the flywheel working exactly as designed — the lab generates real-world evidence while the product scales outside the lab.
Cash Generation and Operating Leverage
The most underappreciated development in Q2 is the step-change in cash generation. “We generated approximately $700,000 in operating cash flow, and we ended the quarter with more than $3 million cash in the bank with an increase of $0.5 million in cash in just this quarter.” — Ilan Danieli, Executive · 2026-08-17 This is 10% of quarterly revenue — a dramatic improvement for a company that relied on dilutive raises in the past. The CEO attributes this to operating leverage: the infrastructure is already built, and incremental revenue falls through to the bottom line. The fundamentals back this up: while free cash flow less SBC is still negative on a TTM basis, the trend is improving sharply, and the recent quarter's operating cash flow was the strongest in years.
The stock tape reflects cautious optimism: the 90-day price action is +11.7% with minimal drawdown, though the long-term chart shows a brutal 99% decline from 2017 peaks. This is a micro-cap ($43M market cap) early-stage turnaround, and the market is just beginning to price in the inflection.
Outlook: Execution is Everything
Management's guidance for H2 2026 is clear: continued revenue growth, product revenue expansion, pipeline conversion, and further operating leverage. The commercial pipeline is expected to start converting to active accounts, which would drive meaningful product revenue contribution. The company also highlighted ongoing marketing and clinical study initiatives around AML to build awareness.
In a sector full of cash-burning diagnostics, Precipio now stands out as a rare self-sustaining growth story. The flywheel is spinning, and the numbers are finally backing up the narrative. The next two quarters will be critical to see if this is a one-off or a sustainable trajectory — but for now, this is one of the more compelling small-cap turnarounds in the diagnostics space.